Venus Medtech (Hangzhou), Inc. Class H (2500) Stock Statistics & Valuation Metrics

Venus Medtech (Hangzhou), Inc. Class H has a market cap or net worth of HK$762.95M. The enterprise value is HK$562.20M.

Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Venus Medtech (Hangzhou), Inc. Class H’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -14.88%.

The current PE Ratio of Venus Medtech (Hangzhou), Inc. Class H is ―. Venus Medtech (Hangzhou), Inc. Class H’s PEG ratio is 0.05.

In the last 12 months, Venus Medtech (Hangzhou), Inc. Class H had revenue of 306.79M and earned -407.69M in profits. Earnings per share was -0.93.

In the last 12 months, operating cash flow was -347.87M and capital expenditures -11.60M, giving a free cash flow of -359.47M billion.

Venus Medtech (Hangzhou), Inc. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Venus Medtech (Hangzhou), Inc. Class H upcoming earnings date is Aug 27, 2026, TBA (Confirmed).

Venus Medtech (Hangzhou), Inc. Class H as a current ratio of 2.77, with Debt / Equity ratio of 12.27%

In the past 12 months, Venus Medtech (Hangzhou), Inc. Class H has paid 2.81M in taxes.

Venus Medtech (Hangzhou), Inc. Class H EV to EBITDA ratio is -3.10, with an EV/FCF ratio of -2.94.

Venus Medtech (Hangzhou), Inc. Class H has HK$280.52M in cash and marketable securities with HK$216.43M in debt, giving a net cash position of HK$64.09M billion.

Gross margin is 69.05%, with operating margin of -112.56%, and net profit margin of -132.89%.

The average price target for Venus Medtech (Hangzhou), Inc. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―